AZN240705P77000
- 0.10
- 0.000.00%
AstraZeneca Newsroom
GLP-1 Analogues Market Forecast: USD 471.1 Billion by 2032 With a 33.2% CAGR | MarketsandMarkets
CHICAGO, July 11, 2024 /PRNewswire/ -- The global GLP-1 analogues market is poised for substantial growth, projected to expand from USD 47.4 billion in 2024 to USD 471.1 billion by 2032, at a robust
The Zacks Analyst Blog Highlights Novo Nordisk, AbbVie, AstraZeneca, Air T and United-Guardian
Three UK Exchange Stocks Estimated To Be Valued Up To 39.2% Below Intrinsic Worth
Top Stock Reports for Novo Nordisk, AbbVie & AstraZeneca
Deutsche Numis Reaffirms Their Hold Rating on AstraZeneca (AZN)
Express News | AstraZeneca : BMO Raises Target Price to $89 From $82
Barclays Sticks to Its Buy Rating for AstraZeneca (AZN)
Radioligand Therapies Market to Show Immense Growth by 2034, Predicts DelveInsight | Key Companies - Curium US, Eli Lilly, Point Biopharma, Fusion, Astrazeneca
The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with cancer, the growing
AstraZeneca PLC (AZN): Is This FTSE Dividend Stock a Good Buy Right Now?
AstraZeneca: Strong Sales Growth and Upward Guidance Potential Justify Buy Rating
The Zacks Analyst Blog Highlights Eli Lilly, Sanofi Merck, AstraZeneca's and Roche
SmartCella Raises EUR 50 Million to Accelerate Growth and Commercialization
STOCKHOLM, July 8, 2024 /PRNewswire/ -- SmartCella Holding AB ("SmartCella") today announces a new share issue raising approximately EUR 50 million to accelerate growth and support commercialization
AstraZeneca's (AZN.US) Tagrisso small molecule combination therapy has been approved again.
According to the Zhitong Finance APP, AstraZeneca (AZN.US) announced today that its epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib) combined with pemetrexed and platinum chemotherapy has been approved in the European Union for first-line treatment of advanced epidermal growth factor receptor mutated non-small cell lung cancer (NSCLC) in adult patients who have exon 19 deletion or exon 21 (L858R) mutation. Tagri
Express News | First-line treatment for advanced cancer! The small molecule combination therapy of Astrazeneca has been approved again.
What the U.K. Election Means for Oil Stocks and Other Sectors -- Barrons.com
By Brian Swint U.K. voters gave the biggest election victory to the Labour Party since former Prime Minister Tony Blair's landslide win in 1997. If history is anything to go by, that could be a boon
Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD
AstraZeneca's (AZN) Tagrisso Gets EU Nod for First-Line NSCLC
Investors in AstraZeneca (LON:AZN) Have Seen Strong Returns of 115% Over the Past Five Years
The European Commission Approves AstraZeneca's Tagrisso (Osimertinib) With Pemetrexed And Platinum-Based Chemotherapy As 1st-line Treatment For Advanced EGFR-Mutated Non-small Cell Lung Cancer Whose Tumors Have Exon 19 Deletions Or Exon 21 Mutations
The European Commission Approves AstraZeneca's Tagrisso (Osimertinib) With Pemetrexed And Platinum-Based Chemotherapy As 1st-line Treatment For Advanced EGFR-Mutated Non-small Cell Lung Cancer Whose T
EU Approves AstraZeneca's Tagrisso Combo as Non-small Cell Lung Cancer Treatment
AstraZeneca (AZN.L, AZN.ST) said Friday the European Union approved Tagrisso plus pemetrexed and platinum-based chemotherapy as a first-line treatment for adults with advanced epidermal growth factor receptor-mutated non-small cell lung cancer.